Tag: 2004

Prevalence of chronic disabling fatigue in children and adolescents

Abstract:

BACKGROUND: The epidemiology of chronic fatiguing illnesses in young people is poorly understood.

AIMS: To estimate the lifetime prevalence of different definitions of chronic fatigue in 8- to 17-year-olds.

METHOD: Participants came from two population-based twin series. Parents completed self-report questionnaires that inquired whether either child had ever experienced more than a few days of disabling fatigue. Telephone interviews were undertaken for individuals who had experienced such an episode.

RESULTS: Questionnaires were returned by 1468 families (65% response rate) and telephone interviews were undertaken regarding 99 of the 129 subjects (77%) who had experienced fatigue. The lifetime prevalence estimates ranged from 2.34% (95% CI 1.75-2.94) for disabling fatigue lasting 3 months to 1.29% (95% CI 0.87-1.71) for a disorder resembling adult operationally defined chronic fatigue syndrome.

CONCLUSIONS: From the age of 11 years, young people have similar rates and types of chronic fatiguing illnesses to adults.

 

Source: Farmer A, Fowler T, Scourfield J, Thapar A. Prevalence of chronic disabling fatigue in children and adolescents. Br J Psychiatry. 2004 Jun;184:477-81. http://bjp.rcpsych.org/content/184/6/477.long  (Full article)

 

General practitioners’ perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: qualitative study

Abstract:

OBJECTIVES: To compare general practitioners’ perceptions of chronic fatigue syndrome and irritable bowel syndrome and to consider the implications of their perceptions for treatment.

DESIGN: Qualitative analysis of transcripts of group discussions.

PARTICIPANTS AND SETTING: A randomly selected sample of 46 general practitioners in England.

RESULTS: The participants tended to stereotype patients with chronic fatigue syndrome as having certain undesirable traits. This stereotyping was due to the lack of a precise bodily location; the reclassification of the syndrome over time; transgression of social roles, with patients seen as failing to conform to the work ethic and “sick role” and conflict between doctor and patient over causes and management. These factors led to difficulties for many general practitioners in managing patients with chronic fatigue syndrome. For both conditions many participants would not consider referral for mental health interventions, even though the doctors recognised social and psychological factors, because they were not familiar with the interventions or thought them unavailable or unnecessary.

CONCLUSIONS: Barriers to the effective clinical management of patients with irritable bowel syndrome and chronic fatigue syndrome are partly due to doctors’ beliefs, which result in negative stereotyping of patients with chronic fatigue syndrome and the use of management strategies for both syndromes that may not take into account the best available evidence.

Comment in: Patient organisations in ME and CFS seek only understanding. [BMJ. 2004]

 

Source: Raine R, Carter S, Sensky T, Black N. General practitioners’ perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: qualitative study. BMJ. 2004 Jun 5;328(7452):1354-7. Epub 2004 May 28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420289/ (Full article)

 

Disability and chronic fatigue syndrome: a focus on function

Abstract:

BACKGROUND: Evidence was sought in the published literature on how best to measure, monitor, and treat disability in patients with chronic fatigue syndrome (CFS).

METHODS: A systematic review was performed of English-language literature published between January 1, 1988, and November 15, 2001. Interventional and observational studies of adults with CFS were eligible if they reported measures of disability and employment. A qualitative synthesis of results relating impairment measures to employment was performed.

RESULTS: Of 3840 studies identified, 37 reported employment status and some measure of mental or physical impairment associated with disability. Most patients with CFS in these studies were unemployed. In 22 studies, the employment status of control subjects was also available. Only depression seemed to be associated with unemployment in patients with CFS. No other measurable impairment seemed to be consistently associated with disability or work outcomes. Only cognitive behavior therapy, rehabilitation, and exercise therapy interventions were associated with restoring the ability to work. No specific patient characteristics were identified as best predictors of positive employment outcomes. No quantitative syntheses of results were performed.

CONCLUSIONS: For questions of disability and employment in CFS, the limitations inherent in the current literature are extensive. Methodologically rigorous, longitudinal, and interventional studies are needed to determine baseline characteristics that are associated with the inability to work and interventions that are effective in restoring the ability to work in the CFS population. Simple and consistent evaluations of functional capacity in patients with CFS are needed.

 

Source: Ross SD, Estok RP, Frame D, Stone LR, Ludensky V, Levine CB. Disability and chronic fatigue syndrome: a focus on function. Arch Intern Med. 2004 May 24;164(10):1098-107. http://www.ncbi.nlm.nih.gov/pubmed/15159267

 

Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome

Abstract:

The objective of this study was to evaluate and compare the basal circadian and pulsatile architecture of the HPA axis in groups of patients with FMS, CFS, or both syndromes with individually matched control groups.

Forty patients with either FMS (n = 13), FMS and CFS (n = 12), or CFS (n = 15) were matched by age (18-65), sex, and menstrual status to healthy controls. Subjects were excluded if they met criteria for major Axis I psychiatric disorders by structured clinical interview (SCID). Subjects were admitted to the General Clinical Research Center where meals and activities were standardized. Blood was collected from an intravenous line every 10 min over 24 h for analysis of ACTH and cortisol. Samples were evaluable for ACTH in 36 subject pairs and for cortisol in 37 subject pairs.

There was a significant delay in the rate of decline from acrophase to nadir for cortisol levels in patients with FMS (P <.01). Elevation of cortisol in the late evening quiescent period was evident in half of the FMS patients compared with their control group, while cortisol levels were numerically, but not significantly, lower in the overnight period in patients with CFS compared with their control group. Pulsatility analyses did not reveal statistically significant differences between patient and control groups.

We conclude that the pattern of differences for basal circadian architecture of HPA axis hormones differs between patients with FMS and CFS compared to their matched control groups. The abnormalities in FMS patients are consistent with loss of HPA axis resiliency.

 

Source: Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, McClure LA, Brown MB, Demitrack MA. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun. 2004 Jul;18(4):314-25. http://www.ncbi.nlm.nih.gov/pubmed/15157948

 

Exercise lowers pain threshold in chronic fatigue syndrome

Abstract:

Post-exertional muscle pain is an important reason for disability in patients who are diagnosed to have Chronic Fatigue Syndrome (CFS). We compared changes in pain threshold in five CFS patients with five age and sex matched controls following graded exercise. Pain thresholds, measured in the skin web between thumb and index finger, increased in control subjects with exercise while it decreased in the CFS subjects. Increased perception of pain and/or fatigue after exercise may be indicative of a dysfunction of the central anti-nociceptive mechanism in CFS patients.

 

Source: Whiteside A, Hansen S, Chaudhuri A. Exercise lowers pain threshold in chronic fatigue syndrome. Pain. 2004 Jun;109(3):497-9. http://www.ncbi.nlm.nih.gov/pubmed/15157711

 

Biologically active food additives for correction of the chronic fatigue syndrome

Abstract:

The syndrome of chronic fatigue is a rather new pathology, included in ADS 10. There is no specific treatment. Vitamins and microelements are very important for the prevention and treatment of CFS. Of special significance are BAA on the basis of yeasts, which are universal in their biological chemical composition and contain high amounts of vitamins B, K and essential amino acids. The aim this work is clinical diagnostic of “Nagipol” use, made on the basis of beer yeasts, for the prevention and treatment of CFS. Clinical-dietologic study showed that “Nagipol” biologically active additive, useful in CFS, proving clinical status improvement in CFS, positively influencing cognitive CNS functions, symptoms of psychoemotional instability, normalizing blood biochemical parameters, can be recommended as one of the addition element in diet-therapy of patients with excessive body mass and obesity with the associated CFS. Recommended “Nagipol” as preventive-medical dietetic means for this pathology.

 

Source: Dotsenko VA, Mosiĭchuk LV, Paramonov AE. Biologically active food additives for correction of the chronic fatigue syndrome. Vopr Pitan. 2004;73(2):17-21. [Article in Russian] http://www.ncbi.nlm.nih.gov/pubmed/15154366

 

Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome

Comment on: Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. [QJM. 2004]

 

Sir,

I read Severens et al.’s article on the cost-effectiveness of cognitive behaviour therapy for patients with unexplained chronic fatigue1 with interest, although as several subjects met the CDC criteria for ‘idiopathic chronic fatigue’ rather than ‘chronic fatigue syndrome’,2,,3 I prefer to use the term ‘unexplained chronic fatigue’ as defined by Fukuda et al.3 to describe the patient sample under consideration.

To be able to regard the presented cost estimates as a valid reflection of the medical costs of patients with unexplained chronic fatigue, it is imperative to demonstrate that there are no differences between participants who are included in the analysis and participants who are excluded from the analysis.

According to the authors: ‘An extensive comparison between participants in the cost-effectiveness analyse (n = 171) and the remaining clinical study participants (n = 99) did not reveal any statistically significant differences regarding age, duration of CFS complaints, and scores for Sickness Impact Profile, Karnofsky score, physical activity, a self-efficacy scale, a causal attribution list, and functional impairment.’ (pp. 158–9).

Although details are lacking in the article, baseline data of the included and excluded participants are available from a publication of the Health Care Insurance Board of the Netherlands (College voor zorgverzekeringen).4 Comparing baseline variables of the two groups using two-tailed independent sample t-tests yields the results that are presented in Table 1. The table shows that physical activity (measured by a motion-sensing device called the actometer), self-efficacy, and psychological well-being (measured by the symptom checklist 90) are significantly different at the 0.05 level. The p values for physical activity (p = 0.0081) and self-efficacy (p = 0.0046) are particularly small.

You can read the rest of this comment here: http://qjmed.oxfordjournals.org/content/97/6/379.long

 

Source: Stouten B. Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. QJM. 2004 Jun;97(6):379-80. http://qjmed.oxfordjournals.org/content/97/6/379.long (Full article)

 

Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome

Sir,

In their economic evaluations of treatments for chronic fatigue syndrome (CFS), Severens et al. compared the cost-effectiveness of cognitive behaviour therapy (CBT) with those of other interventions, and found that the percentage of CFS patients who improved with CBT performed for 8 months was 31% vs. 9% and 12% for other treatments. Considering that, in one study, 28% of CFS patients treated with low-dose hydrocortisone over just one month virtually recovered,  Severens et al. also should have compared the cost-effectiveness of CBT with that of low-dose hydrocortisone.

Treatment with low-dose hydrocortisone for CFS, besides being intuitively far less costly than CBT, is also better-founded clinically than any psychological therapy, because hydrocortisone corrects the hypocortisolism that characterizes at least some CFS patients. Given that ‘frank hypocortisolism’, rather surprisingly, was one of the exclusion criteria for enrolment in the trial of Cleare et al., the percentage of CFS patients who can be effectively treated with low-dose hydrocortisone in day-to-day health care is likely to be higher than the 28% found in that trial.

You can read the rest of this comment here: http://qjmed.oxfordjournals.org/content/97/6/378.long

Comment on: Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. [QJM. 2004]

 

Source: Baschetti R. Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. QJM. 2004 Jun;97(6):378-9. http://qjmed.oxfordjournals.org/content/97/6/378.long (Full article)

 

Cortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones

Abstract:

We investigated abnormalities of the hypothalamic-pituitary-gonadal axis and cortisol concentrations in women with fibromyalgia and chronic fatigue syndrome (CFS) who were in the follicular phase of their menstrual cycle, and whether their scores for depressive symptoms were related to levels of these hormones.

A total of 176 subjects participated – 46 healthy volunteers, 68 patients with fibromyalgia, and 62 patients with CFS. We examined concentrations of follicle-stimulating hormone, luteinizing hormone (LH), estradiol, progesterone, prolactin, and cortisol. Depressive symptoms were assessed using the Beck Depression Inventory (BDI).

Cortisol levels were significantly lower in patients with fibromyalgia or CFS than in healthy controls (P < 0.05); there were no significant differences in other hormone levels between the three groups. Fibromyalgia patients with high BDI scores had significantly lower cortisol levels than controls (P < 0.05), and so did CFS patients, regardless of their BDI scores (P < 0.05). Among patients without depressive symptoms, cortisol levels were lower in CFS than in fibromyalgia (P < 0.05).

Our study suggests that in spite of low morning cortisol concentrations, the only abnormalities in hypothalamic-pituitary-gonadal axis hormones among follicular-phase women with fibromyalgia or CFS are those of LH levels in fibromyalgia patients with a low BDI score. Depression may lower cortisol and LH levels, or, alternatively, low morning cortisol may be a biological factor that contributes to depressive symptoms in fibromyalgia. These parameters therefore must be taken into account in future investigations.

 

Source: Gur A, Cevik R, Nas K, Colpan L, Sarac S. Cortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones.  Arthritis Res Ther. 2004;6(3):R232-8. Epub 2004 Mar 15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC416440/ (Full article)

 

Heresies in textbook on psychiatry

In journal no. 5/2004( 1 ) reported Textbook of Psychiatry by Ulrik Fredrik Malt et al ( 2 ). This book contains erroneous information relating to the description of neurasthenia. The authors classify chronic fatigue syndrome (CFS), post-viral fatigue syndrome (PVFS) and myalgic encephalomyelitis (ME) as neurasthenia, diagnosis code F48.0, and has thus reclassified suffering from a neurological condition to be a psychiatric condition. This was done in Malts first textbook of psychiatry, published in 1994.

WHO has since 1969 classified Thurs the 1st as neurological disease and is not going to change that in the upcoming revision. The English psychiatrists Simon Wessely, Michael Sharpe and their counterparts, often called Wessely School, has spent countless publications in more than a decade trying to to psychiatric ME / CFS, which in part has been internationally condemned.

Leading Norwegian psychiatrists are influenced by Wessely School doctrine, and this doctrine has been continued in Textbook of Psychiatry ( 2 ). In WHO’s Guide to mental health in primary care , which Wessely has helped to develop, is ME / CFS wrongly classified under mental disorders, F48.0. Wrong classification has been debated in the British House several times. WHO were involved and confirmed that ME / CFS should continue to be classified under G93.3 and that no disease can be classified in more than one category. According to ICD-10 is to be post-viral fatigue syndrome specifically excluded before the diagnosis neurasthenia set. Secretary of State for the UK Department of Health, Lord Warner, had in the House of Lords regret their statements in support of Wessely misclassification.

Director of WHO’s Collaborating Centre at King’s College London, Professor Rachel Jenkins has had to bow and accept the WHO’s official position, namely that ME / CFS should be classified under G93.3. The book is stopped and will come in a revised edition. When a country has accepted WHO’s regulations, it is mandatory to follow ICDs classification.

Malt and employee classification of ME / CFS in Textbook of Psychiatry ( 2 ) is contrary to the WHO system. It is highly regrettable that new generations healthcare are taught in heresy by reading the chapter on psychosomatic disorders in this book. In my view, the discussion of ME / CFS is removed, the book withdrawn and come out in a revised edition.

A consensus panel of medical experts has developed new clinical criteria for ME / CFS ( 3 ) These criteria provide a more accurate description of reality.

You can read the full letter here: http://tidsskriftet.no/article/1015463

 

Source: E. Stormorken. Heresies in textbook on psychiatry. Tidsskr Nor Laegeforen. 2004 May 6;124(9):1277; author reply 1277. [Article in Norwegian] http://tidsskriftet.no/article/1015463 (Full article)